[{"address1": "321 Harrison Avenue", "address2": "11th Floor, Suite 1", "city": "Boston", "state": "MA", "zip": "02118", "country": "United States", "phone": "617 453 3596", "website": "https://www.pyxisoncology.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 44, "companyOfficers": [{"maxAge": 1, "name": "Dr. Lara S. Sullivan M.D., MBA", "title": "CEO, President, Chief Medical Officer & Director", "fiscalYear": 2024, "totalPay": 1057225, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jitendra  Wadhane C.A., CPA", "age": 44, "title": "Chief Accounting Officer, Senior VP of Finance, Corporate Controller & Principal Financial Officer", "yearBorn": 1980, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Balu N. Balasubramanian Ph.D.", "title": "Interim Chief Technology Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jan  Pinkas Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alex  Kane M.B.A.", "title": "Senior Vice President of Investor Relations & Capital Markets", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Donna  Regalado", "title": "Head of Human Resources", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Charles T. Gombar Ph.D.", "title": "Senior Vice President of Portfolio & Program Management", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen T. Worsley MBA", "age": 60, "title": "Senior VP & Chief Business Officer", "yearBorn": 1964, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael  Bui", "title": "Head of Global Regulatory Affairs", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Supriya  Roth Ph.D.", "title": "Head of Commercial Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 5.28, "open": 5.3, "dayLow": 5.0959, "dayHigh": 5.42, "regularMarketPreviousClose": 5.28, "regularMarketOpen": 5.3, "regularMarketDayLow": 5.0959, "regularMarketDayHigh": 5.42, "payoutRatio": 0.0, "beta": 1.412, "forwardPE": -4.3613443, "volume": 311266, "regularMarketVolume": 311266, "averageVolume": 824696, "averageVolume10days": 602420, "averageDailyVolume10Day": 602420, "bid": 5.13, "ask": 5.21, "bidSize": 3, "askSize": 3, "marketCap": 323151296, "fiftyTwoWeekLow": 0.833, "fiftyTwoWeekHigh": 5.55, "allTimeHigh": 19.0, "allTimeLow": 0.833, "priceToSalesTrailing12Months": 114.59266, "fiftyDayAverage": 3.5568, "twoHundredDayAverage": 1.798, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 265968272, "profitMargins": 0.0, "floatShares": 41131118, "sharesOutstanding": 62264215, "sharesShort": 4541093, "sharesShortPriorMonth": 4250799, "sharesShortPreviousMonthDate": 1760486400, "dateShortInterest": 1763078400, "sharesPercentSharesOut": 0.0729, "heldPercentInsiders": 0.23292999, "heldPercentInstitutions": 0.38754, "shortRatio": 6.11, "shortPercentOfFloat": 0.088199995, "impliedSharesOutstanding": 62264215, "bookValue": 1.107, "priceToBook": 4.688347, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -97086000, "trailingEps": -1.58, "forwardEps": -1.19, "enterpriseToRevenue": 94.315, "enterpriseToEbitda": -3.305, "52WeekChange": 1.595, "SandP52WeekChange": 0.1326145, "quoteType": "EQUITY", "currentPrice": 5.19, "targetHighPrice": 9.0, "targetLowPrice": 5.0, "targetMeanPrice": 7.675, "targetMedianPrice": 8.0, "recommendationMean": 1.33333, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 8, "totalCash": 76256000, "totalCashPerShare": 1.225, "ebitda": -80469000, "totalDebt": 19073000, "quickRatio": 3.934, "currentRatio": 4.286, "totalRevenue": 2820000, "debtToEquity": 27.731, "revenuePerShare": 0.046, "returnOnAssets": -0.34326, "returnOnEquity": -0.87284, "grossProfits": 2820000, "freeCashflow": -40940624, "operatingCashflow": -72365000, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -29.30248, "financialCurrency": "USD", "symbol": "PYXS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1764367143, "regularMarketTime": 1764352800, "exchange": "NMS", "messageBoardId": "finmb_629268721", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "shortName": "Pyxis Oncology, Inc.", "longName": "Pyxis Oncology, Inc.", "ipoExpectedDate": "2021-10-08", "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "marketState": "CLOSED", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1633699800000, "postMarketChangePercent": -3.0867074, "postMarketPrice": 5.0298, "postMarketChange": -0.16020012, "regularMarketChange": -0.0900002, "regularMarketDayRange": "5.0959 - 5.42", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 824696, "fiftyTwoWeekLowChange": 4.357, "fiftyTwoWeekLowChangePercent": 5.230492, "fiftyTwoWeekRange": "0.833 - 5.55", "fiftyTwoWeekHighChange": -0.36000013, "fiftyTwoWeekHighChangePercent": -0.06486489, "fiftyTwoWeekChangePercent": 159.5, "earningsTimestamp": 1762176600, "earningsTimestampStart": 1762176600, "earningsTimestampEnd": 1762176600, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -1.58, "epsForward": -1.19, "epsCurrentYear": -1.295, "priceEpsCurrentYear": -4.0077224, "fiftyDayAverageChange": 1.6332002, "fiftyDayAverageChangePercent": 0.45917684, "twoHundredDayAverageChange": 3.3920002, "twoHundredDayAverageChangePercent": 1.8865408, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "regularMarketChangePercent": -1.70455, "regularMarketPrice": 5.19, "displayName": "Pyxis Oncology", "trailingPegRatio": null, "__fetch_time": "2025-11-29"}]